Aktis Oncology, Inc.

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the potential of targeted radiopharmaceuticals for a broad range of cancer patients. The company aims to reach patient populations not currently served by existing radiopharmaceutical technologies. While current marketed targeted radiopharmaceuticals, which target prostate specific membrane antigen or somatostatin-2 receptor, are approved for only one tumor type each, they have demonstrated significant commercial success and have become key components of cancer treatment. Aktis Oncology believes there is a substantial opportunity to develop next-generation technologies that broaden the range of tumor targets for which alpha-emitting radioisotopes can be safely delivered. To support patient demand, Aktis Oncology is developing an efficient end-to-end supply chain, combining internal capabilities with external vendors. This strategy aims to maximize clinical utility across multiple indications and tumor types, and to expand the commercial use of radiopharmaceuticals beyond traditional nuclear medicine into broader clinical oncology settings. The company has developed a proprietary miniprotein radioconjugate platform. These miniprotein radioconjugates are designed to selectively deliver tumor-killing radioisotopes to targeted tumors, achieving high tumor penetration and prolonged tumor retention, while rapidly clearing from normal organs and tissues to minimize systemic radiation exposure. Aktis Oncology's miniproteins have shown the ability to potently bind to tumor targets that are not within the scope of current delivery technologies, such as peptide-based radioconjugates.